AR has been implicated in the etiology of secondary complications of diabetes, and AR inhibitor (ARI) epalrestat has been widely adopted in clinical management of secondary diabetic complications in mainland China 17 and Japan 18. The gene discussed is AR; the disease is diabetes mellitus.